MedTrace Logo

Dynamics in Bone Turnover Markers During and After Short-term Glucocorticoid Treatment in Patients With an Inflammatory Joint Disease

NCT06395883 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2025-08-24

No results posted yet for this study

Summary

Bone turnover markers (BTMs) are recommended as an important tool in follow-up of osteoporosis treatment. However, there is a lack of knowledge in the reliability of BTMs during and after glucocorticoid treatment. Glucocorticoids suppresses BTMs during treatment with at least 30% and, moreover, glucocorticoids increase the risk of fractures. Patients with an inflammatory joint disease are at increased risk of osteoporosis, and disease flares are often treated with glucocorticoids, which in turn can lead to loss in reliability of the BTMs in patients who also are on osteoporosis treatment.

There is a need of more knowledge on BTM changes during and after glucocorticoid treatment for optimized patientcare, reduced risk of side effects and reduced health economic costs.

Conditions

  • Osteoporosis
  • Osteoporosis, Steroid Induced
  • Inflammatory Rheumatism

Interventions

DRUG

Glucocorticoid Effect

Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.

Sponsors & Collaborators

  • Vestre Viken Hospital Trust

    collaborator OTHER

  • Hormone Laboratory, Aker University Hospital, Oslo, Norway

    collaborator OTHER

  • Diakonhjemmet Hospital

    lead OTHER

Eligibility

Min Age
25 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-01
Primary Completion
2026-06-30
Completion
2028-12-31

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06395883 on ClinicalTrials.gov